Compare
Sarepta Therapeutics, Inc. vs Royalty Pharma plc vs PTC Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
| Latest fiscal year | Sarepta Therapeutics, Inc. SRPT | Royalty Pharma plc RPRX | PTC Therapeutics, Inc. PTCT | Amneal Pharmaceuticals, Inc. AMRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.20B | $2.38B | $1.73B | $3.02B |
| Revenue growth (YoY) | +15.6% | +5.1% | +114.5% | +8.0% |
| Gross margin | n/a | n/a | n/a | 36.9% |
| Operating margin | -31.8% | 65.6% | 50.1% | 13.1% |
| Net margin | -32.5% | 32.4% | 39.4% | 2.4% |
| Net income | -$713.41M | $770.95M | $682.64M | $72.06M |
| EPS (Diluted) | -$7.13 | $1.78 | $7.78 | $0.22 |
| Operating cash flow | -$205.48M | $2.49B | $711.20M | $339.99M |
| Free cash flow | -$307.45M | n/a | $702.34M | $269.93M |
| Cash & equivalents | $801.28M | $618.70M | $984.65M | $282.03M |
| Total assets | $3.35B | $19.62B | $2.90B | $3.68B |
| Total liabilities | $2.21B | $9.91B | $3.10B | n/a |
| Shareholders' equity | $1.14B | $9.71B | -$205.31M | -$70.79M |
| Return on year-end equity | -62.5% | 7.9% | n/a | n/a |
| Shares outstanding | 104.96M | n/a | 81.47M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Sarepta Therapeutics, Inc. | Royalty Pharma plc | PTC Therapeutics, Inc. | Amneal Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $2.20B Ended 2025-12-31 | $2.38B Ended 2025-12-31 | $1.73B Ended 2025-12-31 | $3.02B Ended 2025-12-31 |
| 1 year earlier | $1.90B Ended 2024-12-31 | $2.26B Ended 2024-12-31 | $806.78M Ended 2024-12-31 | $2.79B Ended 2024-12-31 |
| 2 years earlier | $1.24B Ended 2023-12-31 | $2.35B Ended 2023-12-31 | $937.82M Ended 2023-12-31 | $2.39B Ended 2023-12-31 |
| 3 years earlier | $933.01M Ended 2022-12-31 | $2.24B Ended 2022-12-31 | $698.80M Ended 2022-12-31 | $2.21B Ended 2022-12-31 |
| 4 years earlier | $701.89M Ended 2021-12-31 | $2.29B Ended 2021-12-31 | $538.59M Ended 2021-12-31 | $2.09B Ended 2021-12-31 |